India Pharma - Acute Therapies Drag Overall IPM Growth For September: Motilal Oswal

Motilal Oswal Report

The Indian Pharma Market grew 5.1% YoY in Sep-24 (versus 7.6% in Aug-24 and 8.9% in Sep-23).

Cardiac/Derma/Anti-diabetic therapies grew at 9.7%/8.3%/7.7%, while slower growth was experienced by Respiratory/AI, which declined 1.1%/0.3% YoY.

For the 12 months ending in Sep-24, IPM grew 7.7% YoY, led by price growth/new launches, which contributed 4.2%/2.7% YoY to the overall growth.

However, volume growth was moderate at 0.8% YoY in Sep-24.

IPM’s top brand, Augmentin, experienced a decline of 2% YoY to Rs 730 million with a market share of 0.4% in Sep-24.

Out of the top 10 brands, Udiliv/Thyronorm clocked 16.5%/10.2% YoY growth of Rs 569/Rs 572 million in Sep-24.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.